ADTX Aditxt Inc
11,743
$2.07
$0.03
(1.43%)
| Watchers | 11,743 |
| 52-Wk Low | $1.95 |
| 52-Wk High | $68.08 |
| Market Cap | $4.12M |
| Volume | 16,435.00 |
| 52-Wk High | $68.08 |
| 52-Wk Low | $1.95 |
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness Wire • 6 days ago
Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Aditxt, Inc. (Aditxt or the Company) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR...
Aditxt's wholly owned subsidiary, Adivir, Inc. will acquire all issued and outstanding Class A common shares of Appili in the transaction. Appili has developed FDA-approved Likmez (previously...
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 PR Newswire SAN DIEGO, March 27, 2024 -- Third Consecutive Year of...
Evofem Negotiates Improved Rebate for Hormone-Free 'In the Moment' Contraceptive PHEXXI with Medi-Cal Evofem Negotiates Improved Rebate for Hormone-Free 'In the Moment"...
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy For Women Using GLP-1...
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 PR...